BR112020002104A2 - análogos de 1,2-di-hidro-3h-pirazolo[3,4-d]pirimidin-3-ona - Google Patents
análogos de 1,2-di-hidro-3h-pirazolo[3,4-d]pirimidin-3-ona Download PDFInfo
- Publication number
- BR112020002104A2 BR112020002104A2 BR112020002104-0A BR112020002104A BR112020002104A2 BR 112020002104 A2 BR112020002104 A2 BR 112020002104A2 BR 112020002104 A BR112020002104 A BR 112020002104A BR 112020002104 A2 BR112020002104 A2 BR 112020002104A2
- Authority
- BR
- Brazil
- Prior art keywords
- cancer
- alkyl
- optionally substituted
- unsubstituted
- compound according
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762539734P | 2017-08-01 | 2017-08-01 | |
| US62/539,734 | 2017-08-01 | ||
| PCT/US2018/044580 WO2019028008A1 (en) | 2017-08-01 | 2018-07-31 | 1,2-DIHYDRO-3H-PYRAZOLO [3,4-D] PYRIMIDIN-3-ONE ANALOGUES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112020002104A2 true BR112020002104A2 (pt) | 2020-08-04 |
Family
ID=65233095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020002104-0A BR112020002104A2 (pt) | 2017-08-01 | 2018-07-31 | análogos de 1,2-di-hidro-3h-pirazolo[3,4-d]pirimidin-3-ona |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11124518B2 (enExample) |
| EP (1) | EP3661918B1 (enExample) |
| JP (1) | JP7203816B2 (enExample) |
| KR (1) | KR20200034781A (enExample) |
| CN (1) | CN111094253B (enExample) |
| AR (1) | AR112774A1 (enExample) |
| AU (1) | AU2018312448B2 (enExample) |
| BR (1) | BR112020002104A2 (enExample) |
| CA (1) | CA3071405A1 (enExample) |
| ES (1) | ES2980537T3 (enExample) |
| IL (1) | IL272262A (enExample) |
| MX (1) | MX2020001235A (enExample) |
| RU (1) | RU2020105058A (enExample) |
| SG (1) | SG11202000789WA (enExample) |
| TW (1) | TW201910335A (enExample) |
| WO (1) | WO2019028008A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019074979A1 (en) * | 2017-10-09 | 2019-04-18 | Girafpharma, Llc | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
| WO2019074981A1 (en) | 2017-10-09 | 2019-04-18 | GiraFpharma LLC | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
| CA3088997A1 (en) * | 2018-02-28 | 2019-09-06 | The Regents Of The University Of Colorado, A Body Corporate | Wee1 kinase inhibitors and methods of treating cancer using the same |
| US11261192B2 (en) * | 2018-03-09 | 2022-03-01 | Recurium Ip Holdings, Llc | Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones |
| CN110872296B (zh) * | 2018-08-31 | 2023-05-23 | 上海弘翊生物科技有限公司 | 一种二氢异吲哚-1H-吡唑并[3,4-d]嘧啶酮化合物、其制备方法和应用 |
| US20220220115A1 (en) * | 2019-04-09 | 2022-07-14 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
| EP3952876A4 (en) * | 2019-04-09 | 2023-04-19 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AND THEIR USES |
| WO2020210375A1 (en) * | 2019-04-09 | 2020-10-15 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
| WO2020210320A1 (en) * | 2019-04-11 | 2020-10-15 | Recurium Ip Holdings, Llc | Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones |
| CN112142748B (zh) * | 2019-06-28 | 2023-07-04 | 上海医药集团股份有限公司 | 一种吡唑酮并嘧啶类化合物、其制备方法及应用 |
| CN112142747B (zh) | 2019-06-28 | 2024-03-01 | 上海医药集团股份有限公司 | 一种吡唑酮并嘧啶类化合物、其制备方法及应用 |
| CN112442049A (zh) * | 2019-09-03 | 2021-03-05 | 微境生物医药科技(上海)有限公司 | 作为Wee1抑制剂的嘧啶衍生物 |
| MX2022005402A (es) | 2019-11-15 | 2022-07-11 | Recurium Ip Holdings Llc | Sintesis quiral de un alcohol terciario. |
| JP7631348B2 (ja) * | 2019-12-20 | 2025-02-18 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | 組み合わせ |
| CA3182270A1 (en) * | 2020-05-15 | 2021-11-18 | Recurium Ip Holdings, Llc | Mono- and combination therapies |
| US12522607B2 (en) | 2020-06-17 | 2026-01-13 | Wigen Biomedicine Technology (shanghai) Co., Ltd. | Substituted pyrazolo[3,4-d]pyrimidines as wee-1 inhibitors |
| WO2022011391A1 (en) | 2020-07-09 | 2022-01-13 | Recurium Ip Holdings, Llc | Salts and forms of a wee1 inhibitor |
| CN114805357B (zh) * | 2021-01-21 | 2023-12-19 | 四川大学 | 一种靶向setdb1-ttd的小分子抑制剂及其制药用途 |
| EP4332104A4 (en) * | 2021-04-30 | 2025-04-16 | Wigen Biomedicine Technology (Shanghai) Co., Ltd. | Fused ring compound as a WEE-1 inhibitor, as well as production process and use thereof |
| KR20240044409A (ko) * | 2021-06-04 | 2024-04-04 | 아프레아 테라퓨틱스, 인크. | Wee1 키나아제 저해제로서 유용한 피리도피리미딘 유도체 |
| WO2023016417A1 (zh) * | 2021-08-11 | 2023-02-16 | 微境生物医药科技(上海)有限公司 | 作为Wee-1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮化合物 |
| CN117940430B (zh) * | 2021-09-22 | 2025-10-31 | 微境生物医药科技(上海)有限公司 | 作为Wee-1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮化合物 |
| WO2023166080A1 (en) | 2022-03-01 | 2023-09-07 | Step Pharma S.A.S. | Combination treatments comprising a ctps1 inhibitor and a wee1 inhibitor |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1846408B1 (en) | 2005-01-14 | 2013-03-20 | Janssen Pharmaceutica NV | 5-membered annelated heterocyclic pyrimidines as kinase inhibitors |
| PE20080695A1 (es) * | 2006-04-27 | 2008-06-28 | Banyu Pharma Co Ltd | Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel |
| US8329711B2 (en) * | 2007-10-23 | 2012-12-11 | Msd K.K. | Pyridone-substituted-dihydropyrazolopyrimidinone derivative |
| US9266895B2 (en) * | 2012-09-10 | 2016-02-23 | Principia Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors |
| GB201612092D0 (en) * | 2016-07-12 | 2016-08-24 | Almac Discovery Ltd | Pharmaceutical compounds |
-
2018
- 2018-07-31 MX MX2020001235A patent/MX2020001235A/es unknown
- 2018-07-31 TW TW107126578A patent/TW201910335A/zh unknown
- 2018-07-31 SG SG11202000789WA patent/SG11202000789WA/en unknown
- 2018-07-31 US US16/635,348 patent/US11124518B2/en active Active
- 2018-07-31 ES ES18842344T patent/ES2980537T3/es active Active
- 2018-07-31 AU AU2018312448A patent/AU2018312448B2/en not_active Ceased
- 2018-07-31 CN CN201880059242.4A patent/CN111094253B/zh active Active
- 2018-07-31 JP JP2020505356A patent/JP7203816B2/ja active Active
- 2018-07-31 WO PCT/US2018/044580 patent/WO2019028008A1/en not_active Ceased
- 2018-07-31 KR KR1020207005636A patent/KR20200034781A/ko not_active Ceased
- 2018-07-31 CA CA3071405A patent/CA3071405A1/en active Pending
- 2018-07-31 RU RU2020105058A patent/RU2020105058A/ru unknown
- 2018-07-31 EP EP18842344.6A patent/EP3661918B1/en active Active
- 2018-07-31 BR BR112020002104-0A patent/BR112020002104A2/pt not_active Application Discontinuation
- 2018-08-01 AR ARP180102185A patent/AR112774A1/es not_active Application Discontinuation
-
2020
- 2020-01-26 IL IL272262A patent/IL272262A/en unknown
-
2021
- 2021-06-15 US US17/304,154 patent/US20210317124A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2020105058A3 (enExample) | 2021-11-17 |
| WO2019028008A1 (en) | 2019-02-07 |
| CN111094253A (zh) | 2020-05-01 |
| KR20200034781A (ko) | 2020-03-31 |
| JP7203816B2 (ja) | 2023-01-13 |
| CN111094253B (zh) | 2023-08-29 |
| TW201910335A (zh) | 2019-03-16 |
| IL272262A (en) | 2020-03-31 |
| RU2020105058A (ru) | 2021-09-02 |
| AU2018312448B2 (en) | 2022-09-15 |
| ES2980537T3 (es) | 2024-10-01 |
| US20200157112A1 (en) | 2020-05-21 |
| EP3661918A1 (en) | 2020-06-10 |
| US11124518B2 (en) | 2021-09-21 |
| US20210317124A1 (en) | 2021-10-14 |
| EP3661918A4 (en) | 2021-05-12 |
| JP2020529993A (ja) | 2020-10-15 |
| AR112774A1 (es) | 2019-12-11 |
| EP3661918C0 (en) | 2024-05-08 |
| AU2018312448A1 (en) | 2020-02-13 |
| CA3071405A1 (en) | 2019-02-07 |
| MX2020001235A (es) | 2020-07-20 |
| EP3661918B1 (en) | 2024-05-08 |
| SG11202000789WA (en) | 2020-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7203816B2 (ja) | １，２－ジヒドロ－３Ｈ－ピラゾロ［３，４－ｄ］ピリミジン－３－オン類似体 | |
| JP7726563B2 (ja) | 置換１，２－ジヒドロ－３Ｈ－ピラゾロ［３，４－ｄ］ピリミジン－３－オン | |
| ES2797955T3 (es) | Moduladores de la ruta de hedgehog | |
| WO2023049691A1 (en) | Cdk7 inhibitors and methods of treating cancer | |
| IL293939A (en) | Macrocyclic compounds | |
| RU2847224C2 (ru) | Замещенные 1,2-дигидро-3н-пиразоло[3,4-d]пиримидин-3-оны | |
| RU2812726C2 (ru) | Замещенные 1,2-дигидро-3н-пиразоло[3,4-d]пиримидин-3-оны | |
| HK40043303B (en) | Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones | |
| HK40043303A (en) | Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones | |
| CN115666574A (zh) | 组合 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |